Source: Pharmac
31 July 2020
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018 and the 2019/20 Invitation to Tender, dated 1 November 2019.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by:
- For new listings, by 4pm on 12 August 2020 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or the new listing date above (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Hydrocortisone |
Crm 1%; |
$17.15 |
$17.15 |
Hydrocortisone (PSM) |
1 September 2020 |
1 December 2020 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Hydrocortisone |
Crm 1%; |
$17.15 |
$17.15 |
Hydrocortisone (PSM) |
1% |
1 September 2020 |
1 December 2020 |
2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Bupropion hydrochloride |
Tab modified-release 150 mg; |
$11.00 |
$11.00 |
Zyban |
1 December 2020 |
1 March 2021 |
|
Cyproterone acetate with ethinyloestradiol |
Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs; |
$4.67 |
$4.98 |
Ginet |
1 January 2021 |
1 April 2021 |
|
Losartan potassium |
Tab 12.5 mg; |
$1.39 |
$1.56 |
Losartan Actavis |
1 October 2020 |
1 January 2021 |
|
Losartan potassium |
Tab 25 mg; |
$1.63 |
$1.84 |
Losartan Actavis |
1 October 2020 |
1 January 2021 |
|
Losartan potassium |
Tab 50 mg; |
$2.00 |
$2.25 |
Losartan Actavis |
1 October 2020 |
1 January 2021 |
|
Losartan potassium |
Tab 100 mg; |
$2.31 |
$3.50 |
Losartan Actavis |
1 October 2020 |
1 January 2021 |
|
Naltrexone hydrochloride |
Tab 50 mg; |
$112.55 |
$133.33 |
Naltraccord |
1 October 2020 |
1 January 2021 |
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Sole Subsidised Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Goserelin |
Implant 3.6 mg, syringe; |
$66.48 |
$65.68 |
Goserelin-Teva |
1 December 2020 |
1 May 2021 |
Zoladex |
|
Goserelin |
Implant 10.8 mg, syringe; |
$177.50 |
$122.37 |
Goserelin-Teva |
1 December 2020 |
1 May 2021 |
Zoladex |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Bupropion hydrochloride |
Tab modified-release 150 mg; |
$11.00 |
$11.00 |
Zyban |
1% |
1 December 2020 |
1 March 2021 |
|
Cyproterone acetate with ethinyloestradiol |
Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs; |
$4.67 |
$4.98 |
Ginet |
1% |
1 January 2021 |
1 April 2021 |
|
Losartan potassium |
Tab 12.5 mg; |
$1.39 |
$1.56 |
Losartan Actavis |
1% |
1 October 2020 |
1 January 2021 |
|
Losartan potassium |
Tab 25 mg; |
$1.63 |
$1.84 |
Losartan Actavis |
1% |
1 October 2020 |
1 January 2021 |
|
Losartan potassium |
Tab 50 mg; |
$2.00 |
$2.25 |
Losartan Actavis |
1% |
1 October 2020 |
1 January 2021 |
|
Losartan potassium |
Tab 100 mg; |
$2.31 |
$3.50 |
Losartan Actavis |
1% |
1 October 2020 |
1 January 2021 |
|
Naltrexone hydrochloride |
Tab 50 mg; |
$112.55 |
$133.33 |
Naltraccord |
1% |
1 October 2020 |
1 January 2021 |
6. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand (Supplier) |
DV Limit |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Goserelin |
Implant 3.6 mg, syringe; 1 prefilled syringe pack |
$66.48 |
$65.68 |
Goserelin-Teva |
1% |
1 December 2020 |
1 May 2021 |
Zoladex |
|
Goserelin |
Implant 10.8 mg, syringe; 1 prefilled syringe pack |
$177.50 |
$122.37 |
Goserelin-Teva |
1% |
1 December 2020 |
1 May 2021 |
Zoladex |
|
Metronidazole |
Inj 5 mg per ml, 100 ml bag; |
$55.00 |
$27.50 |
Baxter |
1% |
1 September 2020 |
1 February 2021 |
AFT (bottle) |
Tender declines – Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2018/19 Invitation to Tender, dated 1 November 2018, and
- the 2019/20 Invitation to Tender, dated 1 November 2019.
2018/19 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Adapalene |
Crm 0.1% |
|
Adapalene |
Gel 0.1% |
|
Amoxicillin clavulanate |
Inj 500 mg with clavulanic acid 100 mg |
|
Amoxicillin clavulanate |
Inj 1000 mg with clavulanic acid 200 mg |
|
Beclomethasone dipropionate |
Metered aqueous nasal spray, 50 mcg per dose |
|
Beclomethasone dipropionate |
Metered aqueous nasal spray, 100 mcg per dose |
|
Bupivacaine hydrochloride with glucose |
Inj 0.5% with glucose, 4 ml ampoule |
|
Fentanyl |
Inj 20 mcg per ml, 100 ml bag |
|
Fentanyl |
Inj 10 mcg per ml, 50 ml prefilled syringe |
|
Fentanyl |
Inj 10 mcg per ml, 10 ml syringe |
|
Ganciclovir |
Inj 500 mg |
|
Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride |
Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet |
|
Minocycline hydrochloride |
Cap 100 mg |
|
Pemetrexed |
Powder for infusion, 500 mg |
|
Sodium citrate |
Oral liq 8.8% (300 mmol/l) |
2019/20 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Carvedilol |
Tab 6.25 mg |
|
Carvedilol |
Tab 12.5 mg |
|
Carvedilol |
Tab 25 mg |
|
Diclofenac sodium |
Inj 25 mg per ml, 3 ml |
|
Ibuprofen |
Tab 200 mg |
|
Glyceryl trinitrate |
Spray 400 mcg per dose |
|
Lacosamide (current access) |
Inj 10 mg per ml, 20 ml |
|
Lacosamide (current access) |
Tab 50 mg |
|
Lacosamide (current access) |
Tab 100 mg |
|
Lacosamide (current access) |
Tab 150 mg |
|
Lacosamide (current access) |
Tab 200 mg |
|
Lacosamide (widened access) |
Tab 50 mg |
|
Lacosamide (widened access) |
Tab 100 mg |
|
Lacosamide (widened access) |
Tab 150 mg |
|
Lacosamide (widened access) |
Tab 200 mg |
|
Oestradiol |
Tab 1 mg |
|
Oestradiol |
Tab 2 mg |
|
Oestradiol |
TDDS 25 mcg per day |
|
Oestradiol |
TDDS 50 mcg per day |
|
Oestradiol |
TDDS 75 mcg per day |
|
Oestradiol |
TDDS 100 mcg per day |
|
Oestradiol with norethisterone |
Tab 1 mg with 0.5 mg norethisterone acetate |
|
Oestradiol with norethisterone |
Tab 2 mg with 1 mg norethisterone acetate |
|
Oestradiol with norethisterone |
Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg (oestradiol tab (12) and 1 mg oestradiol tab (6) |
For products included in the 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.
Last updated: 31 July 2020
